Monopar Therapeutics MNPR
$69.00 −$1.29 (-1.84%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $67.35 -2.40%
Open$68.50
Prev close$70.29
Day range$67.36 – $69.86
Volume132.6K
Market cap$467.60M
P/E (TTM)–
Dividend yield–
MNPR Stock News
Headlines matching Monopar Therapeutics or the MNPR ticker, most recent first.
- Piper Sandler Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $123 Positive
- H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $125
- H.C. Wainwright Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)
- Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $145 Positive
- Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $130 Positive
- A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $125 to $133
- Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $125
- Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $115
- H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $125 Positive
- BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $117
- Lake Street Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $103
- A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $101 to $130
- BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $117 Positive
- H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $105
- Piper Sandler Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $101
No comments yet — be the first to weigh in on MNPR.
Sign in to join the discussion.